| Written | 2000-12 | Jean-Loup Huret |
| Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France |
| This article is an update of : |
| 2000-10 | Maité P Prosperi, Didier Ferbus, Gérard.Goubin | |
| Laboratoire d'Oncogenese, UMR147 CNRS, Section de recherche, Institut Curie, Paris, France. |
| Identity |
| Alias (NCBI) | PAGA (Proliferation Associated Gene A) | PAG | PRX1 | Hs.1163 | NKEFA (natural killer-enhancing factor A) | Prx-1 (peroxiredoxin 1) | HBP23 (Heme-binding protein 23 kDa) | MSP23 (macrophage 23-kD stress protein) |
| HGNC (Hugo) | PRDX1 |
| HGNC Alias symb | NKEFA |
| HGNC Previous name | PAGA |
| LocusID (NCBI) | 5052 |
| Atlas_Id | 266 |
| Location | 1p34.1 [Link to chromosome band 1p34] |
| Location_base_pair | Starts at 45511051 and ends at 45521884 bp from pter ( according to GRCh38/hg38-Dec_2013) [Mapping PRDX1.png] |
| Fusion genes (updated 2017) | Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands) |
| HS2ST1 (1p22.3) / PRDX1 (1p34.1) | PRDX1 (1p34.1) / AKR1A1 (1p34.1) | PRDX1 (1p34.1) / PRDX1 (1p34.1) | |
| PRDX1 (1p34.1) / TNFAIP3 (6q23.3) | PRDX1 (1p34.1) / WDR59 (16q23.1) | SNRNP40 (1p35.2) / PRDX1 (1p34.1) | |
| USP16 (21q21.3) / PRDX1 (1p34.1) |
| Note | PAGA/NKEFA/PRDX1/peroxiredoxin 1, located in 1p34, is often confused in databases and elsewhere with PAGB/TDPX2, a pseudogene located in 9p22; PAGB is not either NKEFB/PRDX2/peroxiredoxin 2, located in 13q12; the other peroxiredoxins, PRDX3 and PRDX5, are located in 10q25-26 and in 11q13 respectively |
| DNA/RNA |
| Description | 6 exons, 13 kb |
| Transcription | 937 bp mRNA; 599 bp coding sequence |
| Pseudogene | pseudogene in 9p22 |
| Protein |
| Description | 199 amino acids; 22 kDa; form dimers through a disulfide bridge |
| Expression | widely expressed, in particular in the various cell types of the central nervous system and in red blood cells; overexpressed following induction of proliferation and oxidative stress |
| Localisation | cytosolic |
| Function | antioxidant, against oxidative stress; Abl SH3-binding protein; inhibitor of c-Abl tyrosine kinase activity; also binds to heme |
| Homology | thioperoxiredoxines |
| Implicated in |
| Note | |
| Disease | Correlations between the expression level and the stage of tumor progrssion in squamous cell carcinoma of the oral cavity; high expression in follicular thyroid tumors, but not in papillary carcinoma of the thyroid |
| Bibliography |
| Crystal structure of a multifunctional 2-Cys peroxiredoxin heme-binding protein 23 kDa/proliferation-associated gene product. |
| Hirotsu S, Abe Y, Okada K, Nagahara N, Hori H, Nishino T, Hakoshima T |
| Proceedings of the National Academy of Sciences of the United States of America. 1999 ; 96 (22) : 12333-12338. |
| PMID 10535922 |
| Characterization of a mammalian peroxiredoxin that contains one conserved cysteine. |
| Kang SW, Baines IC, Rhee SG |
| The Journal of biological chemistry. 1998 ; 273 (11) : 6303-6311. |
| PMID 9497358 |
| Peroxiredoxin I (macrophage 23 kDa stress protein) is highly and widely expressed in the rat nervous system. |
| Mizusawa H, Ishii T, Bannai S |
| Neuroscience letters. 2000 ; 283 (1) : 57-60. |
| PMID 10729633 |
| The pag gene product, a physiological inhibitor of c-abl tyrosine kinase, is overexpressed in cells entering S phase and by contact with agents inducing oxidative stress. |
| Prospéri MT, Ferbus D, Rouillard D, Goubin G |
| FEBS letters. 1998 ; 423 (1) : 39-44. |
| PMID 9506838 |
| Differential expression of peroxiredoxin subtypes in human brain cell types. |
| Sarafian TA, Verity MA, Vinters HV, Shih CC, Shi L, Ji XD, Dong L, Shau H |
| Journal of neuroscience research. 1999 ; 56 (2) : 206-212. |
| PMID 10494109 |
| Recombinant natural killer enhancing factor augments natural killer cytotoxicity. |
| Sauri H, Ashjian PH, Kim AT, Shau H |
| Journal of leukocyte biology. 1996 ; 59 (6) : 925-931. |
| PMID 8691079 |
| Antioxidant function of recombinant human natural killer enhancing factor. |
| Sauri H, Butterfield L, Kim A, Shau H |
| Biochemical and biophysical research communications. 1995 ; 208 (3) : 964-969. |
| PMID 7702627 |
| Cloning and sequence analysis of candidate human natural killer-enhancing factor genes. |
| Shau H, Butterfield LH, Chiu R, Kim A |
| Immunogenetics. 1994 ; 40 (2) : 129-134. |
| PMID 8026862 |
| Identification of natural killer enhancing factor as a major antioxidant in human red blood cells. |
| Shau H, Kim A |
| Biochemical and biophysical research communications. 1994 ; 199 (1) : 83-88. |
| PMID 8123050 |
| The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. |
| Wen ST, Van Etten RA |
| Genes & development. 1997 ; 11 (19) : 2456-2467. |
| PMID 9334312 |
| Peroxiredoxin I expression in oral cancer: a potential new tumor marker. |
| Yanagawa T, Iwasa S, Ishii T, Tabuchi K, Yusa H, Onizawa K, Omura K, Harada H, Suzuki H, Yoshida H |
| Cancer letters. 2000 ; 156 (1) : 27-35. |
| PMID 10840156 |
| Citation |
| This paper should be referenced as such : |
| Huret, JL |
| PRDX1 (peroxiredoxin 1) |
| Atlas Genet Cytogenet Oncol Haematol. 2001;5(1):14-15. |
| Free journal version : [ pdf ] [ DOI ] |
| History of this paper: |
| Prosperi, MP ; Ferbus, D ; Goubin, G. PAG (proliferation associated gene A). Atlas Genet Cytogenet Oncol Haematol. 2000;4(4):192-192. |
| http://documents.irevues.inist.fr/bitstream/handle/2042/37668/10-2000-PAGID266.pdf |
| Other Leukemias implicated (Data extracted from papers in the Atlas) [ 1 ] |
|
t(X;21)(p22;q22) RUNX1/PRDX4
|
| Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 2 ] |
|
t(1;1)(p22;p34) HS2ST1/PRDX1
PRDX1/AKR1A1 (1p34) |
| External links |
| REVIEW articles | automatic search in PubMed |
| Last year publications | automatic search in PubMed |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Fri Feb 19 17:56:53 CET 2021 |
For comments and suggestions or contributions, please contact us